Please login to the form below

Not currently logged in
Email:
Password:

ramucirumab

This page shows the latest ramucirumab news and features for those working in and with pharma, biotech and healthcare.

EMA says Lilly’s Lartruvo should not be prescribed

EMA says Lilly’s Lartruvo should not be prescribed

along with other newer cancer drugs such as Cyramza (ramucirumab).

Latest news

More from news
Approximately 9 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics